| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-11-07 |
| タイトル |
|
|
タイトル |
Real-world effectiveness and lung abnormalities associated with amikacin liposome inhalation suspension |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Mycobacterium avium complex |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Nontuberculous mycobacteria |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
ALIS |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Japan |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Amikacin |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Tokita, Nozomi
Ito, Masashi
Urabe, Naohisa
Fujiwara, Keiji
Furuuchi, Koji
Kodama, Tatsuya
Ohe, Takashi
Kurosaki, Atsuko
Tanaka, Yoshiaki
Yoshiyama, Takashi
Kishi, Kazuma
Ohta, Ken
Morimoto, Kozo
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: The guideline recommends the addition of amikacin liposome inhalation suspension (ALIS) for patients with refractory Mycobacterium avium complex pulmonary disease (MAC-PD). However, factors influencing culture conversion and managing ALIS-related adverse events, particularly ALIS-related lung abnormalities (ALIS-RLAs) remain insufficient. Methods: This was a two-center retrospective cohort study involving 87 patients with refractory MAC-PD who received ALIS from August 2021 to September 2023. Refractory MAC-PD was defined as failure to achieve sputum culture conversion after six months or more of guideline-based therapy. On the basis of data obtained from medical records, adverse events were assessed in 76 patients, whereas treatment outcomes were evaluated in 49 patients. Results: The sputum culture conversion rate was 28.6 %. Prognostic factors associated with a negative impact included a body mass index below 18.5 kg/m2 (adjusted odds ratio [aOR], 0.07, 95 % confidence interval [CI], 0.02–0.35) and the presence of cavities (aOR 0.02, 95 % CI 0.002–0.18). Patients achieved culture conversion had a shorter interval from MAC-PD treatment initiation to ALIS administration. The most frequent adverse event was dysphonia, which occurred in 53.9 %. ALIS-RLAs were observed in 82.1 %: 53 patients (79.1 %) had multiple nodular patterns, 18 patients (26.9 %) had organizing pneumonia patterns, one patient (1.5 %) had a diffuse alveolar pattern, and another (1.5 %) had a hypersensitivity pneumonitis pattern. Among patients with ALIS-RLAs, 92.7 % were asymptomatic, and 85.5 % were able to continue ALIS. Conclusion: Initiating ALIS before significant progression is important. Although ALIS-RLAs were observed in 82.1 % of patients, discontinuation of ALIS appeared unnecessary in asymptomatic cases. |
|
言語 |
en |
| 書誌情報 |
en : Respiratory Medicine
巻 248,
p. art. no. 108408,
発行日 2025-10-14
|
| 出版者 |
|
|
出版者 |
Elsevier Ltd |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
09546111 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1016/j.rmed.2025.108408 |
| 権利 |
|
|
権利情報 |
© 2025 Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Respiratory Medicine, 248, art. no. 108408; 2025 |
|
言語 |
en |
RM248_108408.pdf (7.2 MB)
